Alzheimer s Disease research hub

TSPO Modulation in AD

This study looks at a new drug, XBD173, for Alzheimer’s disease. It wants to see if the drug can improve how blood flows to the brain, which is important for brain health and memory. The drug is taken for 28 days.

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

This study looks at a new drug, lecanemab, to see if it can fully remove amyloid plaques in people with a rare, inherited form of Alzheimer's. It also checks if removing these plaques can slow down how quickly the disease progresses.

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

This study is looking into a new treatment called KarXT + KarX-EC for people with mild to moderate Alzheimer's disease. Researchers want to see if it can help improve memory and thinking, and if it's safe to use.

An Investigation Into the Feasibility of Beetroot Juice Supplementation in People Living With Alzheimer's Disease.

This study looks at whether people with Alzheimer's can easily drink beetroot juice regularly. Researchers want to see if drinking beetroot juice twice a day for one week can improve health for those with mild or moderate Alzheimer’s disease.

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

This study is testing a new medication called RO7812653 for early Alzheimer's disease. Researchers want to see if it's safe, how the body handles it, and if it has any effects. They are comparing it to a dummy treatment (placebo) in people aged 50-75.

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

This study is looking at different ways of giving a medicine called donanemab for early Alzheimer's disease. Researchers want to see how different doses affect side effects and which patients might be more likely to experience them. It's for adults aged 60-85.

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

This study is looking at a new treatment called ACI-24.060. It aims to see if it's safe and how it works in people with early Alzheimer's disease and adults with Down Syndrome who have signs of Alzheimer's. The goal is to understand if it can help prevent or slow down these conditions.

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

This study is looking into a new treatment called VHB937 for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and helps with memory and daily activities. It involves taking the treatment or a dummy pill and having regular check-ups.

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

This study is testing a new medicine, GSK4527226, for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and helps improve or slow down symptoms compared to a dummy medicine.

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

This study, called TRAILRUNNER-ALZ 3, is looking at a new medicine called Remternetug for people in the early stages of Alzheimer's disease. Researchers want to see if it can slow down memory, thinking, or daily living problems compared to a dummy drug (placebo).

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

This study looks for early signs of Alzheimer's disease by examining blood, brain scans, and digital information. It aims to find new ways to spot the disease before it gets worse, especially in people with memory problems or those who are still healthy.

Open-label Extension Study in Participants With Early Alzheimer's Disease

This study is looking into a new medication called GSK4527226 for people with early Alzheimer's disease. It's an extension of an earlier study, meaning everyone in this new phase will receive the treatment. We're checking how safe and effective it is over the long term.

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

This study is for people aged 60-85 at risk of Alzheimer's or with very early memory problems. It tests a new potential medicine, RO7269162, to see if it's safe and affects the disease. Participants will receive the new medicine or a dummy treatment, with regular check-ups.

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

This study is testing a new medicine called ALN-5288 for people with Alzheimer's disease. Researchers want to see if it's safe and how it affects the body and the disease. Some people will get the study drug, and others will get a dummy medicine.

A PHASE 1B DOSE RANGE FINDING STUDY OF PHENSERINE COMPARED TO DONEPEZIL IN PARTICIPANTS WITH EARLY OR MILD ALZHEIMER’S DISEASE

This study is looking at a new drug called phenserine for people with early or mild Alzheimer's disease. Researchers want to see how different doses of phenserine affect changes in the brain, and compare it to a common Alzheimer's drug called donepezil.

A phase 1, controlled, open-label, single dose, dose-escalation, clinical proof-of-concept study of MRI enhanced with ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in patients with brain amyloid deposits as demonstrated by amyloid PET

This study is looking at a new injection called ADx-001 that might help doctors see signs of Alzheimer's disease in the brain more clearly on MRI scans. It's an early-stage study to see if it's safe and how it works in people.

A randomised, double-blind, placebo-controlled phase Ib trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ACD856 in healthy participants

This study is testing a new medicine, ACD856, in healthy people. We want to see if it's safe, how well the body handles it, and what it does. This research could help us learn more about treating conditions like depression or Alzheimer's disease.

Randomised, crossover bioequivalence clinical trial of memantine 20 mg capsules versus memantine 20 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

This study is comparing two ways to take the Alzheimer's medicine memantine: capsules versus coated tablets. Healthy adults will take a single dose to see if both forms work the same way in the body.

A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer’s Disease.

This study is looking at the long-term safety and how well a new medicine, GSK4527226 (also known as AL101), works for people with early Alzheimer's disease. Researchers want to see if it helps with memory and daily activities over a longer period.

A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer’s Disease

This study is looking at a new medicine called ALN-5288 for people with Alzheimer's disease. Researchers want to see if it's safe and how the body handles it. This is a very early stage study, meaning it's the first time this medicine is being given to people.

Dominantly Inherited Alzheimer Network (DIAN)

This study looks for early signs of Alzheimer's disease in people who have a family history of the condition. It aims to find ways to predict who will develop the disease, even before symptoms appear, by studying changes in their body and brain.

I5T-MC-AACQ: Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults with Early Symptomatic Alzheimer’s Disease

A Multicenter, Long-term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants with Alzheimer's Disease

A PHASE 1, OPEN-LABEL, RANDOMIZED, THREE-PERIOD, THREE-TREATMENT, BALANCED, SIX-SEQUENCE CROSSOVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF DIFFERENT HYDROMETHYLTHIONINE MESYLATE (HMTM) TABLET FORMULATIONS AND STRENGTHS IN HEALTHY ADULT SUBJECTS.

Open-Label Extension Study of PRX012 in Subjects with Alzheimer’s Disease Who Were Enrolled in Study PRX012-101 or PRX012-102

A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer’s Disease (AD), Followed by an Open-Label Extension Period

Randomised, crossover bioequivalence clinical trial of donepezil 5 mg capsules vs donepezil 5 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions

A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer's Disease

A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)